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Abstract Melanoma is one of the most aggressive human
cancers.ThevitaminDsystemcontributestothepathogenesis
and prognosis of malignancies including cutaneous mela-
noma.AnexpressionofthevitaminDreceptor(VDR)andan
anti-proliferative effect of vitamin D in melanocytes and
melanoma cells have been shown in vitro. Studies examining
associationsofpolymorphisms ingenes codingfor vitaminD
metabolism-related proteins (1a-hydroxylase [CYP27B1],
1,25(OH)2D-24hydroxylase [CYP24A1], vitamin D-binding
protein [VDBP]) and cancer risk are scarce, especially with
respecttomelanoma.MainlyVDRpolymorphismsregarding
melanoma risk and prognosis were examined although other
vitamin D metabolism-related genes may also be crucial. In
our hospital-based case–control study including 305 mela-
noma patients and 370 healthy controls single nucleotide
polymorphisms in the genes CYP27B1 (rs4646536),
CYP24A1 (rs927650), VDBP (rs1155563, rs7041), and VDR
(rs757343, rs731236, rs2107301, rs7975232) were analyzed
for their association with melanoma risk and prognosis.
Except VDR rs731236 and VDR rs2107301, the other six
polymorphisms have not been analyzed regarding melanoma
before. To further improve the prevention as well as the
treatment of melanoma, it is important to identify further
genetic markers for melanoma risk as well as prognosis in
addition to the crude phenotypic, demographic, and environ-
mentalmarkersusedintheclinictoday.Apanelofgeneticrisk
markers could help to better identify individuals at risk for
melanoma development or worse prognosis. We, however,
found that none of the polymorphisms tested was associated
with melanoma riskaswellasprognosis inlogistic and linear
regression models in our study population.
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Introduction
Cutaneous melanoma represents one of the most aggressive
and treatment-resistant human cancers. The increase of the
annual incidence rate varies between populations. For
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in the order of 3–7 % per year [13]. In Europe, the highest
incidence rates have been reported in Scandinavia (occur-
rence of 15 cases per 100 000 inhabitants per year) and the
lowest in the Mediterranean countries (occurrence of 5–7
cases per 100,000 inhabitants per year) [18]. The risk for
melanoma development increases with age [19] and other
demographic, phenotypic, and environmental risk factors
such as sunlight exposure [3, 28], particularly an inter-
mittent exposure [19], family history of melanoma, dys-
plastic nevi, number of nevi, freckling, fair hair, eye and
skin color [5]. Breslow tumor thickness at presentation
remains the most important single prognostic factor for
patients with cutaneous melanoma [36]. The risk for mel-
anoma metastases and, thus, reduced survival increases
with increasing tumor thickness. Early detection of thin
melanomas is mandatory for a cure. The 5-year survival
rate is *93 % for melanomas with a Breslow tumor
thickness \1.5 mm. The survival rate for melanomas
thicker than 3.5 mm is *37 % [35]. Interestingly, inde-
pendent of any tumor thickness about one-third of the
patients never develop melanoma metastases.
Single nucleotide polymorphisms (SNP) associated with
melanoma susceptibility or the course of disease have been
described as molecular risk factors in genes involved in the
regulation of skin pigmentation, such as the melanocortin-1
receptor gene [38], in DNA repair, such as the xeroderma
pigmentosum group C gene [9], in the detoxiﬁcation of
oxidative stress metabolites, such as the glutathione
S-transferase gene [29], in the regulation of the immune
system, such as the interleukin-10 gene [48], or in the
production of proteins of the steroid and thyroid hormone
superfamily, including the peroxisome proliferator-
activated receptor genes [39].
The vitamin D endocrine system regulates a broad
spectrum of independent biological processes including
innate immune responses, bone metabolism, and cell pro-
liferation and differentiation [23]. Vitamin D, absorbed
from the diet or synthesized in the skin by the action of
sunlight, is metabolized in the liver to 25-hydroxyvitamin
D [25(OH)D] and afterwards in the kidney to 1,25-di-
hydroxyvitamin D [1,25(OH)2D]. There are two important
enzymes involved in the formation of circulating active
vitamin D (1,25(OH)2D3 or calcitriol): The hepatic mito-
chondrial vitamin D 25-hydroxylase (25OHase, CYP27A1)
and the renal mitochondrial enzyme 1a-hydroxylase
(1aOHase, CYP27B1) for 25(OH)D3 and 1,25(OH)2D3,
respectively. The 1,25(OH)2D-24-hydroxylase (24OHase,
CYP24A1) enzyme plays a critical role in the metabolism
of 1,25(OH)2D3 [24, 40]. The active form of vitamin D
(1,25(OH)2D3 or calcitriol) exhibits a potent secosteroid
hormone that binds to a corresponding intranuclear recep-
tor (VDR) in target tissues and thereby mediates its
different regulatory transcriptional activities [6, 53]. The
vitamin D-binding protein (VDBP) may also play a role in
the vitamin D metabolism, because the protein regulates
the circulating level of vitamin D [4, 52].
A contribution of the vitamin D system to the patho-
genesis and prognosis of malignancies including cutaneous
melanoma has been reported [42]. In general 1,25(OH)2D3,
the hormonal derivative of vitamin D3 and the ligand of the
VDR, exhibits anti-proliferative and pro-differentiation
effects in VDR-expressing cell types [16, 37, 43, 49]. It has
been shown that melanocytes as well as melanoma cells
express VDR and that 1,25(OH)2D3 has an anti-prolifera-
tive effect on melanocytes as well as melanoma cells in
vitro [11, 45]. Randerson-Moor et al. [44] showed that that
serum 25-hydroxyvitamin D(3) levels were inversely cor-
related with melanoma Breslow tumor thickness supporting
the view that vitamin D and VDR may inﬂuence melanoma
susceptibility, and putatively melanoma progression even
to a greater extend.
The analysis of polymorphisms in genes of the vitamin
D metabolism concerning their association with melanoma
as well as other types of cancer is a current research topic.
For example, Halsall et al. [22] assessed the association of
a novel adenine–guanine substitution 1,012 bp upstream of
the exon 1a transcription start site (A-1012G) in the VDR
gene with melanoma risk and prognosis in 171 melanoma
patients and 80 healthy controls. The authors found that the
A allele was signiﬁcantly associated with melanoma sus-
ceptibility as well as the development of melanoma
metastases. Santonocito et al. [47] reported a correlation of
the VDR SNP BsmI (rs1544410) with an increased mela-
noma risk as well as a strong association with an increased
Breslow tumor thickness. In another study, the Taq I
(rs731236) and the Fok I (rs2228570) SNPs of the VDR
gene were analyzed for their melanoma risk association.
The Tt and the tt genotypes of the VDR-Taq I-polymor-
phism showed an association with a decreased melanoma
risk compared to the TT genotype, whereas the VDR-Fok I
Ff genotype was associated with an increased risk to
develop melanoma compared to the FF genotype [34]. In a
recent analysis, Orlow et al. analyzed 38 common VDR
gene polymorphisms in relation to melanoma risk in a large
population-based case control study comprising 3,676
individuals with incident primary melanoma [41]. The
authors report modest but statistically signiﬁcant associa-
tions between eight SNPs and the risk of developing sub-
sequent new primary melanomas. These results support the
hypothesis that the vitamin D pathway plays an important
role in the genesis of melanoma [41].
In most studies that investigated the association of
polymorphisms in the vitamin D system and skin cancer risk
VDR gene SNPs were assessed. Information about SNPs in
other vitamin D metabolism-related genes that might
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123contribute to skin cancer or other types of internal cancers is
scarce. Flohil et al. [15] analyzed the SNPs rs7041 and
rs4588 in the VDBP gene for their association with basal
cell carcinoma (BCC). Only the AT variant of rs7041 was
associated with an increased BCC risk in younger patients
after age stratiﬁcation. The minor allele of the CYP24A1
gene SNP rs927650 has been reported to be associated with
a decreased risk of disease recurrence/regression in prostate
cancer patients [26]. The CYP27B1 single nucleotide
polymorphism rs4646536 was not associated with the sus-
ceptibility for developing colon cancer [14].
In our present hospital-based case–control study, we
tested eight vitamin D metabolism-related polymorphisms
focusing on the VDBP gene (rs1155563 and rs7041) and
the genes coding for CYP27B1 and CYP24A1 (rs4646536
and rs927650) for their association with melanoma risk and
melanoma prognosis. In addition, four SNPs in the VDR
gene (rs2107301, rs7975232, rs757343, and rs731236)
were assessed in our 305 melanoma patients and 370
healthy controls study group.
Materials and methods
Study subjects
We analyzed a total study group of 675 probands. The
study group consisted of 305 patients with histopatholog-
ically conﬁrmed cutaneous melanoma and 370 healthy
control donors from the same area (gender and ethnicity
matched). The recruitment period was from 2001 to 2003
in the Departments of Dermatology of the Ludwig-Max-
imilians-University Munich and the Georg-August-Uni-
versity Goettingen. Control probands were recruited from
the donors at blood transfusions services from the same
hospitals as well as from local health care personnel known
personally by the authors. After completion of personal
interviews, blood samples were obtained from each pro-
band and the genomic DNA was extracted and stored. The
following parameters from patients and controls were
registered by standardized procedures: sex, age, hair color,
eye color, skin type, number of nevi (on both forearms,
diameter[2 mm), primary tumor thickness. These studies
were in accordance with the national protocols approved by
the Georg-August-University and Ludwig-Maximilians-
University Institutional Review Boards. Informed consent
was obtained from all the study participants orally as well
as in writing.
Genotyping
The following SNPs were analyzed with pre-designed
genotyping assays: rs731236 (VDR), rs7975232 (VDR),
rs2107301 (VDR), rs757343 (VDR), rs4646536 (CYP27
B1), rs927650 (CYP24A1), rs7041 (VDBP) (assay numbers
C_2404008_10, C_28977635_10, C_16174096_10, C_240
4009_20, C_25623453_10, C_7595497_10, C_31335
94_30, respectively). The SNP rs1155563 (VDBP) was
analyzed using a Custom Taqman SNP Genotyping Assay.
All ready-to-use TaqMan SNP Genotyping assays (409
concentrated) and TaqMan Genotyping Mastermix (29
concentrated) were purchased from Applied Biosystems
(Foster City, USA) and applied according to the manu-
facturer’s instructions. PCR ampliﬁcation was carried out
in 384 well plates (Frame Star 384, purple frame, Thermo
Fisher, Waltham, USA) in an Eppendorf 384-well Mas-
tercycler (Eppendorf, Hamburg, Germany). Reactions were
performed in a total volume of 5 ll including 10 ng
genomic DNA. Genotyping was done using a Taqman
7200 HT (Applied Biosystems, Foster City, USA). For
control purposes, the sex was genetically re-evaluated
using a pre-designed Taqman genotyping assay (AMEL-
XY) as described previously [54]. The genetically deter-
mined sex was discordant in 8 probands (of 683 tested) that
were subsequently excluded from the analysis. For further
control, a minimum of 10 % of all samples were genotyped
in duplicates showing 100 % concordance between the
genotype calls.
Statistics
To determine whether the genotype frequencies conformed
to the HWE, the equivalence test proposed by Wellek was
used (5 % test level) with e = 0.1 that tests for confor-
mation with HWE instead of deviation from HWE [56].
For identiﬁcation of the phenotypic, demographic, and
environmental risk factors relevant in the study, logistic
regression analyses were carried out to predict melanoma
from age, nevus count, and skin type as continuous
covariates, as well as from gender, hair colour (red vs.
other) and eye colour (green or blue vs. grey or brown) as
binary covariates. A backward selection by Akaike Infor-
mation Criterion (AIC) in a stepwise algorithm was con-
ducted. Therefore, the covariates age, nevus count, and
skin type were selected for the logistic regression analyses.
To explore the effect of single polymorphisms, these were
added to an additive and dominant logistic regression
model with adjustment by the selected covariates
(Tables 3, 4). For associations with the Breslow tumor
thickness and log transformed Breslow tumor thickness
additive and dominant linear regression models were esti-
mated including the selected covariates (Tables 5, 6, 7 and
8).
Based on the frequencies of the homozygous normal
genotype observed in our controls, we estimated the power
to detect an OR of 1.5 at a signiﬁcance level of 5 % in a
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123dominant model. The resulting power exceeded 65 % for
all but three SNPs. For these, the estimated power was
36 % (rs2107301), 48 % (rs7041), and 47 % (rs757343).
Results
Study subjects
The analysis included 305 unrelated Caucasian patients
with histopathologically conﬁrmed cutaneous melanoma
and 370 unrelated Caucasian, healthy, cancer-free controls
from the same area. All probands were interviewed in
standardized procedures to register the following demo-
graphic and phenotypic parameters: gender (1: male, 2:
female), age, hair color (1: red, 2: blonde, 3: brown, 4:
black), eye color (1: green, 2: blue, 3: grey, 4: brown), skin
type (I, II, III, IV), number of nevi (on both forearms,
diameter [2 mm), and primary Breslow tumor thickness.
The male:female distribution was 52.1:47.9 % in the mel-
anoma patients and 52.4:47.6 % in the controls. The mean/
median age in the melanoma group was 53.05/55 years and
36.76/34 years in the control group.
Applying logistic regression analysis, there were no
independent associations of gender as well as hair color or
eye color with the susceptibility to develop melanoma in
the study population as indicated in Table 1 (odds ratios
(OR) of 1.09, 0.95, 1.12, respectively). A positive family
history of melanoma was too rare to analyze. However, the
frequencies of the phenotypic and demographic melanoma
risk factors skin type (OR: 0.44), number of nevi (OR:
1.04), and age (OR: 1.09) were different in the melanoma
patient group compared with the control group. A higher
number of nevi was associated with increased melanoma
risk. Fair skin type and older age were also independent
melanoma risk factors (Table 1). This indicates that our
study population is representative of the German popula-
tion as described earlier [9, 10, 48].
Distribution of the polymorphisms
All polymorphisms analyzed in this study have already
been described previously. The SNPs rs4646536 and
rs927650 in CYP27B1 and CYP24A1, respectively, are both
located in intron regions as is the rs1155563 VDBP SNP.
The rs7041 VDBP SNP (Glu432Asp) is located in exon 11.
Three of the VDR SNPs are located in intron regions:
rs757343, rs2107301, and rs7975232. The synonymous
VDR SNP rs731236 is located in exon 9.
Table 2 depicts general information of the eight single
nucleotide polymorphisms investigated concerning allele
frequencies and genotype distributions. All polymorphisms
are quite common. The minor allele frequencies ranged
from 0.11 to 0.49. The genotype frequencies of the poly-
morphisms rs731236, rs7975232, rs7041, rs4646536,
rs927650, rs1155563 conformed to the Hardy–Weinberg
equilibrium (HWE). The SNPs rs2107301 and rs757343
showed a small deviance from HWE, however, could be
incorporated into the further analysis as we performed
several control steps. First, we re-analysed about 10 % of all
samples and found no deviations. Second, we re-assessed
the gender by a pre-designed TaqMan assay (AMELXY).
Polymorphisms and melanoma risk
NeitheroftheeightpolymorphismsinvolvedinthevitaminD
metabolism was found to be associated with the risk to
develop cutaneous melanoma in our study population
applying logistic regression models with age, skin type, and
numberofneviascovariables.Thiswastrueforthedominant
model (Table 3) as well as the additive genetic model
(Table 4). With the dominant model, the CYP27B1
rs4646536aswellastheVDRrs757343andrs2107301SNPs
exhibited the lowest p values of 0.42, 0.65, and 0.56,
respectively, corresponding to ORs of 1.19, 1.12, and 1.22.
Based on the conﬁdence intervals, we can exclude true ORs
forthedominantgenotypeofgreaterthanabouttwoforseven
out of the eight SNPs with a probability of 95 %. With the
additivemodel,thelowestpvalueswerefoundfortheVDBP
SNPs rs1155563 and rs7041 as well as for the VDR
rs2107301 and again for the CYP27B1 rs4646536 corre-
spondingto0.16(OR:0.80),0.44(OR:0.89),0.50(OR:0.90),
and0.58(OR:1.09),respectively.Withaprobabilityof95 %,
we can exclude that the true OR from the additive genetic
model is greater than 1.5 for seven out of the eight SNPs.
Polymorphisms and melanoma prognosis
It is well known that an increased Breslow tumor thickness
is associated with an increased risk for melanoma metas-
tases and, thus, reduced survival. To explore a potential
effect of the SNPs on the risk to develop melanoma
Table 1 Association of demographic and phenotypic markers with
melanoma risk (280 cases and 337 controls)
Risk factors OR 95 % CI p value
Gender
b 1.09 0.72–1.63 0.67
Age
a 1.09 1.07–1.11 10
-4
Skin type
a 0.44 0.33–0.59 10
-4
Hair color
b 0.95 0.69–1.30 0.74
Eye color
b 1.12 0.91–1.36 0.30
Number of nevi
a 1.04 1.03–1.05 10
-4
a Continuous covariates including skin type I–IV (by increase)
b Gender, hair colour (red vs. other) and eye colour (green or blue vs.
grey or brown) as binary covariates
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123metastases a dominant as well as an additive linear
regression model was estimated incorporating the Breslow
tumor thickness as the dependent variable. Applying both
genetic models, the dominant (Table 5) and the additive
model (Table 6), no association of any of the eight poly-
morphisms with the Breslow tumor thickness could be
detected. With the dominant model, the p values ranged
from 0.15 (OR: 0.53) for the VDBP rs1155563 SNP to 0.93
(OR: -0.02) for the CYP27B1 rs4646536 SNP. With the
additive model, the lowest p values were observed for the
VDBP SNPs rs7041 and rs1155563 as well as for the VDR
SNPs rs2107301, rs757343, and rs731236 corresponding to
0.14 (OR: 0.22), 0.17 (OR: 0.22), 0.15 (OR: 0.22), 0.41
(OR: -0.19), and 0.43 (OR: 0.12), respectively. Log
Table 2 Genotype distribution,
Hardy–Weinberg equilibrium,
and allele frequencies
a SNPs were analyzed despite a
small deviance of HWE due to
internal controls
SNP Gene Geno-type hwe A1A1 A1A2 A2A2 Minor allele
frequency
Minor allele
frequency
(HapMap2)
rs4646536 CYP27B1 AG Yes 254 291 72 0.35 0.34
rs927650 CYP24A1 CT Yes 182 314 120 0.45 0.43
rs7041 VDBP AC Yes 105 306 206 0.42 0.43
rs1155563 VDBP GA Yes 315 248 54 0.29 0.29
rs731236 VDR AG Yes 236 281 100 0.39 0.44
rs757343
a VDR CT No 487 126 4 0.11 0.12
rs2107301
a VDR AG No 59 227 331 0.28 0.30
rs7975232 VDR AC Yes 165 299 153 0.49 0.43
Table 3 Association with melanoma risk: results of the dominant
logistic regression model including the demographic and phenotypic
melanoma risk factors age, skin type, and number of nevi as co-
variables (280 cases and 337 controls)
SNP OR 95 % CI p value
rs4646536 (CYP27B1) 1.19 0.79–1.79 0.42
rs927650 (CYP24A1) 0.98 0.62–1.53 0.92
rs7041 (VDBP) 1.01 0.58–1.74 0.99
rs1155563 (VDBP) 0.96 0.45–2.04 0.92
rs731236 (VDR) 0.99 0.65–1.50 0.96
rs757343 (VDR) 1.12 0.69–1.83 0.65
rs2107301 (VDR) 1.22 0.62–2.39 0.56
rs7975232 (VDR) 1.00 0.63–1.58 1.00
Table 4 Association with melanoma risk: results of the additive
logistic regression model including the demographic and phenotypic
melanoma risk factors age, skin type, and number of nevi as co-
variables (280 cases and 337 controls)
SNP OR 95 % CI p value
rs4646536 (CYP27B1) 1.09 0.80–1.48 0.58
rs927650 (CYP24A1) 0.99 0.74–1.33 0.95
rs7041 (VDBP) 0.89 0.66–1.20 0.44
rs1155563 (VDBP) 0.80 0.58–1.10 0.16
rs731236 (VDR) 0.96 0.72–1.28 0.79
rs757343 (VDR) 1.09 0.68–1.74 0.73
rs2107301 (VDR) 0.90 0.67–1.22 0.50
rs7975232 (VDR) 1.00 0.75–1.32 0.98
Table 5 Association with Breslow tumor thickness (melanoma
prognosis): results of the dominant linear regression model including
the demographic and phenotypic melanoma risk factors age, skin
type, and number of nevi as covariables (263 cases included)
SNP OR 95 % CI p value
rs4646536 (CYP27B1) -0.02 -0.43 to 0.39 0.93
rs927650 (CYP24A1) 0.26 -0.18 to 0.69 0.25
rs7041 (VDBP) 0.28 -0.23 to 0.80 0.28
rs1155563 (VDBP) 0.53 -0.19 to 1.25 0.15
rs731236 (VDR) 0.17 -0.24 to 0.57 0.42
rs757343 (VDR) -0.20 -0.68 to 0.29 0.43
rs2107301 (VDR) 0.19 -0.49 to 0.87 0.58
rs7975232 (VDR) 0.14 -0.34 to 0.62 0.57
Table 6 Association with Breslow tumor thickness (melanoma
prognosis): results of the additive linear regression model including
the demographic and phenotypic melanoma risk factors age, skin
type, and number of nevi as covariables (263 cases included)
SNP OR 95 % CI p value
rs4646536 (CYP27B1) 0.01 -0.29 to 0.30 0.96
rs927650 (CYP24A1) 0.02 -0.27 to 0.31 0.89
rs7041 (VDBP) 0.22 -0.07 to 0.50 0.14
rs1155563 (VDBP) 0.22 -0.09 to 0.52 0.17
rs731236 (VDR) 0.12 -0.18 to 0.42 0.43
rs757343 (VDR) -0.19 -0.65 to 0.26 0.41
rs2107301 (VDR) 0.22 -0.08 to 0.52 0.15
rs7975232 (VDR) -0.01 -0.30 to 0.28 0.95
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123transformation of the Breslow tumor thickness neither
changed the results of the dominant nor the additive linear
regression model (Tables 7, 8). Unfortunately, further data
on relapse free survival, or over all melanoma speciﬁc
survival are not documented in our database.
Discussion
Among human cancers, the cutaneous melanoma represents
averyaggressiveandtreatment-resistanttypeofcancerwith
a steeply increasing annual incidence rate [13]. There is a
need to identify further molecular genetic markers for the
susceptibility to develop melanoma in addition to the well
known, but quite crude, environmental, demographic, and
phenotypic markers like sunlight exposure [3, 28], family
history of melanoma, dysplastic nevi, number of nevi,
freckling, fair hair, eye and skin color [5] as well as for a
better estimation of melanoma prognosis [36].
Generally, the vitamin D system regulates different
biological processes. It is involved in the regulation of cell
proliferation and differentiation [23]. The major enzymes
involved in generating the active form of vitamin D are the
hepatic mitochondrial vitamin D-25-hydroxylase (25OH-
ase, CYP27A1) and the renal mitochondrial enzyme
1a-hydroxylase (1aOHase, CYP27B1) [24, 40]. Once
activated, the secosteroid hormone binds to the VDR
receptor. The complex is then internalized and functions as
a transcription factor [6, 53]. While 1,25(OH)2D-24-
hydroxylase (24OHase, CYP24A1) is responsible for the
degradation of the activated vitamin D [24, 40], the vitamin
D-binding protein regulates the circulating level of active
vitamin D [4, 52]. Every single one of these enzymes plays
an essential role in the metabolism of vitamin D: Either in
the formation of active vitamin D, in its action, or in its
degradation. Consequently, every vitamin D-related
enzyme is involved directly or indirectly in the outcome of
the function of the secosteroid hormone. For melanoma
cells as well as melanocytes, an anti-proliferative effect of
1,25(OH)2D3 in vitro has been shown [11, 45]. Reichrath
et al. [46] reported that the VDR receptor is expressed in
primary melanoma tissue. Furthermore associations
between reduced serum levels of 25-hydroxyvitamin D and
cancer have been reported [20, 50, 51].
In this present hospital-based case–control study, we
analyzed putative associations of 8 SNPs in vitamin D
metabolism-related genes with melanoma risk as well as
melanoma prognosis in a study group of 305 melanoma
patients and 375 controls. Most of the studies examining
associations between skin cancer and polymorphisms in the
vitamin D metabolism analyzed polymorphisms in the VDR
gene [27, 33, 34, 47]. Studies about polymorphisms in other
genes contributing to the vitamin D status and their possible
associations to skin cancer risk are rare. To our knowledge,
onlythers7041polymorphisminVDBPgenewasreportedto
be associated with an increased BCC risk [15]. Polymor-
phismsintheothervitaminDmetabolism-relatedgenesmay
also be relevant concerning cancer susceptibility. Polymor-
phismsinthevitaminDmetabolism-relatedgenesCYP24A1
and CYP27B1 were reported to be associated with colon as
well as prostate cancer risk, respectively [8, 14].
We analyzed the rs4646536 SNP in the CYP27B1 gene.
This gene seems relevant for carcinogenesis as other
polymorphisms in this gene were found to be associated
with prostate cancer [26] and colon cancer [14]. The
rs4646536 polymorphism has rarely been analyzed with
respect to cancer susceptibility before. An examination of
this SNP with respect to prostate cancer by Beuten et al. [8]
revealed no association. An association of this SNP with
melanoma was not investigated before.
Dong et al. [14] concluded that the CYP27B1 and
CYP24A1 genes as important players in vitamin D
metabolism have signiﬁcance in colon cancer risk. More-
over, associations of SNPs in the CYP24A1 gene with
Table 7 Association with log-transformed Breslow tumor thickness
(melanoma prognosis): results of the dominant linear regression
model including the demographic and phenotypic melanoma risk
factors age, skin type, and number of nevi as covariables (263 cases
included)
SNP OR 95 % CI p value
rs4646536 (CYP27B1) 0.03 -0.19 to 0.26 0.77
rs927650 (CYP24A1) 0.01 -0.23 to 0.25 0.93
rs7041 (VDBP) 0.14 -0.13 to 0.42 0.31
rs1155563 (VDBP) 0.29 -0.11 to 0.68 0.15
rs731236 (VDR) 0.16 -0.06 to 0.38 0.15
rs757343 (VDR) -0.01 -0.27 to 0.26 0.95
rs2107301 (VDR) -0.03 -0.40 to 0.34 0.86
rs7975232 (VDR) -0.01 -0.27 to 0.25 0.94
Table 8 Association with log-transformed Breslow tumor thickness
(melanoma prognosis): results of the additive linear regression model
including the demographic and phenotypic melanoma risk factors age,
skin type, and number of nevi as covariables (263 cases included)
SNP OR 95 % CI p value
rs4646536 (CYP27B1) 0.06 -0.10 to 0.22 0.48
rs927650 (CYP24A1) -0.05 -0.21 to 0.11 0.56
rs7041 (VDBP) 0.09 -0.06 to 0.24 0.25
rs1155563 (VDBP) 0.10 -0.07 to 0.26 0.27
rs731236 (VDR) 0.12 -0.04 to 0.28 0.15
rs757343 (VDR) -0.02 -0.27 to 0.23 0.88
rs2107301 (VDR) 0.03 -0.13 to 0.20 0.71
rs7975232 (VDR) -0.07 -0.22 to 0.09 0.39
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123prostate cancer prognosis have been reported. The poly-
morphism rs927650 that is analyzed in our present study,
as well as another polymorphism (rs2762939) in the
CYP24A1 gene were signiﬁcantly associated with prostate
cancer prognosis [26]. With regard to melanoma and SNP
rs927650 no previous data exist.
We also analyzed two SNPs in the VDBP gene,
rs1155563 and rs7041. These polymorphisms may have a
functional consequence. Three common haplotypes (GC1S,
GC1F, and GC2) are existent in VDBP that is also referred
to as GC protein. The haplotypes differ in the combination
of two SNPs including rs7041. These haplotypes have been
associated with differences in VDBP and serum 25(OH)D
concentration as well as afﬁnity of VDBP to vitamin D
metabolites. The GC1S and GC1F haplotypes were asso-
ciated with higher levels of VDBP and serum 25(OH)D
concentration as well as higher afﬁnity of VDBP to vitamin
D metabolites compared with the GC2 haplotype [4, 31,
32]. In genome wide association studies of circulating
vitamin D levels, the rs7041 and rs1155563 polymor-
phisms were found to be associated with another common
VDBP SNP, rs 2282679. These three common VDBP
variants, with the rs2282679 prevailing, conferred an
association signal with 25(OH)D levels in metaanalyses [2,
55]. It was recently reported that analysis of HapMap
determined that rs1155563 is in high linkage disequilib-
rium (LD) with rs4588 (LD = 0.83) [25]. The GC2 allele
has been associated with decreased postmenopausal breast
cancer risk [1]. Furthermore, the rs7041 VDBP SNP was
associated with basal cell carcinoma risk [15]. Neither the
rs7041 nor the rs1155563 have ever been analyzed for their
association with melanoma so far.
Polymorphisms in the VDR gene have been analyzed for
their associations with prostate cancer [21], breast cancer
[12], colorectal adenomas [30] and also for their association
with melanomas [27]. However, studies examining the
association between VDR SNPs and melanoma risk and
prognosis are relatively rare compared to the other cancer
types.ThetwoVDRSNPsanalyzedinthisstudy,rs7975232,
and rs757343, have not been investigated for their associa-
tion with melanoma yet. The VDR SNPs rs731236 and
rs2107301 have been analyzed with respect to melanoma
before [7, 17, 27, 33, 34, 41]. Two studies identiﬁed a
decreased melanoma risk in association with rs731236 [33,
34], but most studies could not ﬁnd an association of
rs731236 with melanoma risk or prognosis [7, 17, 27, 41].
After the identiﬁcation of age, skin type, and number of
neviasindependentdemographicandphenotypicmelanoma
risk factors in our study group [9, 48], we analyzed every
single SNP for its association with melanoma risk in a
dominant as well as an additive logistic regression model
integratingtheseriskfactors.Astheprimarytumorthickness
was documented, we also analyzed the association of every
single SNP with melanoma prognosis in a dominant and an
additive linear regression model. In summary, none of the
analyzedSNPsshowedanassociationwithmelanomariskor
melanoma prognosis in our representative study group.
Our study has two major drawbacks. One is the younger
age of the controls. We are aware that a better match of
patients and controls with regard to age would have been
desirable. However, our study population is closely gender
and ethnicity matched as we recruited all probands at only
two university hospitals in Germany. It could be that the
younger controls will develop melanoma at an older age and
thus account as ‘‘false negatives’’. However, this effect may
be counteracted by the effect that our older melanoma
cohort may be enriched for relevant SNPs due to the fact
that controls with the same relevant SNPs may have already
died from other types of cancers at that age. As pointed out,
the vitamin D system-associated polymorphisms may pre-
dispose also to other malignancies. In any case, we have
controlled for age in our multivariate regression analyses to
compensate for that limitation. Further, we are conﬁdent
that our study population is representative as we already
identiﬁed DNA repair gene SNPs [9] and interleukin 10
promoter polymorphisms [48] as independent molecular
melanoma risk factors with this study population.
The second drawback is the limited power of our study,
which is less than 80 % for any SNP for detecting an OR of
1.5. Based on the conﬁdence intervals for the true ORs, we
are able to exclude true ORs of greater than 2.0 in the
dominant and greater than 1.5 in the additive genetic model
for seven out of the eight SNPs, which we view as an
indicator that strong effects of the investigated variants can
be excluded by our study.
Further studies with larger study populations and an
optimized age match of controls seem mandatory.
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